# Kymera Therapeutics

> Clinical-stage biopharmaceutical company in Watertown, Massachusetts building oral
> small-molecule medicines with targeted protein degradation — degraders that recruit
> the body's own protein-disposal machinery to eliminate disease-driving proteins that
> conventional inhibitors cannot drug. Kymera publishes no public developer API,
> developer portal, SDK, or machine-readable API description; this file describes the
> company's public web surface for agents and research tools.

## Company

- [Kymera Therapeutics](https://www.kymeratx.com): Corporate home page.
- [About Us](https://www.kymeratx.com/about-us/): Company overview and mission — "build a global medicines company that harnesses novel modalities to revolutionize healthcare."
- [Leadership](https://www.kymeratx.com/about-us/leadership/): Executive and board leadership.
- [Careers & Culture](https://www.kymeratx.com/careers-culture/): Open roles and culture.
- [Contact Us](https://www.kymeratx.com/contact-us/): Corporate contact — 500 North Beacon Street, 4th Floor, Watertown, MA 02472.

## Science

- [Our Approach](https://www.kymeratx.com/science-innovation/our-approach/): Targeted protein degradation as a disease-agnostic modality where a binding event is sufficient to drive degradation.
- [Pipeline](https://www.kymeratx.com/science-innovation/pipeline/): Clinical and preclinical programs.
- [Resource Library](https://www.kymeratx.com/resource-library/): Publications, posters, and presentations.

## Pipeline programs

- KT-621 — oral STAT6 degrader, Phase 2, wholly owned. Type 2 inflammatory disease: atopic dermatitis, asthma, COPD, eosinophilic esophagitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, prurigo nodularis, bullous pemphigoid.
- KT-579 — first-in-class oral IRF5 degrader, Phase 1, wholly owned. Lupus, Sjogren's syndrome, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis, dermatomyositis.
- KT-485 / SAR447971 — oral IRAK4 degrader, Phase 1, partnered with Sanofi. Hidradenitis suppurativa, atopic dermatitis, rheumatoid arthritis, asthma, IBD.
- KT-200 — CDK2 molecular glue degrader, IND-enabling, partnered with Gilead Sciences. CCNE1-amplified breast cancer and solid tumors.

## Stakeholders

- [Investors](https://investors.kymeratx.com/): Investor relations, filings, and events.
- [Press Releases](https://investors.kymeratx.com/news-events/press-releases): Company news.
- [Media](https://www.kymeratx.com/media/): Media resources.
- [Patients](https://patients.kymeratx.com/): Patient-facing information.

## Optional

- [GitHub](https://github.com/kymeratx): Kymera Therapeutics GitHub organization.
- [LinkedIn](https://www.linkedin.com/company/kymeratherapeutics/)
- [X / Twitter](https://twitter.com/KymeraTx)
- [Terms of Use](https://www.kymeratx.com/terms-of-use/)
- [Privacy Policy](https://www.kymeratx.com/privacy-policy/)

## Notes for agents

- No public API, OpenAPI/AsyncAPI description, MCP server, SDK, CLI, sandbox, or OAuth surface is published by Kymera Therapeutics as of 2026-07-19.
- No /.well-known/ discovery documents (security.txt, openid-configuration, oauth-authorization-server, api-catalog, ai-plugin.json) are served on any Kymera host.
- No vulnerability-disclosure program, bug bounty, or trust center was found on the public site.
- investors.kymeratx.com is fronted by a bot-filtering CDN and returns 403 to unauthenticated automated requests.